Posted by Michael Wonder on 18 Sep 2017
Amicus Therapeutics announces approval for Galafold (migalastat) for treatment of Fabry disease in Canada
14 September 2017 - First oral precision medicine for Fabry disease with broad label for Fabry patients with amenable genetic mutations.
Amicus Therapeutics announced that Health Canada has approved the oral precision medicine Galafold for long-term treatment of adults with a confirmed diagnosis of Fabry disease [deficiency of alpha-galactosidase (alpha-Gal A)] and who have an alpha-Gal A mutation determined to be amenable by an in vitro assay.
Following the Health Canada approval, Amicus expects to make Galafold available to Canadian patients in the coming weeks.
